Skip to main content

Table 4 Sensory nerve conduction tests in patients with HD, ALS or CSA

From: Electrophysiological differences between Hirayama disease, amyotrophic lateral sclerosis and cervical spondylotic amyotrophy

 

Median nerve

Ulnar nerve

U/M ratio

 

Amplitude (μV)

CV (m/s)

Amplitude (μV)

CV (m/s)

Amplitude

CV

HD

Affected limb

50.1 ± 13.2&

62.1 ± 6.4&

42.5 ± 13.7&

60.1 ± 5.5

0.9 ± 0.4

1.0 ± 0.1

 

Healthy limb

50.4 ± 12.1

61.2 ± 6.4

44.9 ± 11.4

60.5 ± 6.2

0.9 ± 0.3

1.0 ± 0.1

ALS

Affected limb

31.7 ± 14.3*&

57.5 ± 8.3*&

31.9 ± 13.4*&

56.6 ± 6.9*&

0.9 ± 0.3

0.9 ± 0.1

 

Healthy limb

37.6 ± 12.3*

57.8 ± 5.9*

34.8 ± 13.1*

56.2 ± 5.2*

0.9 ± 0.3

1.0 ± 0.1

CSA

Affected limb

38.9 ± 13.2*&

57.6 ± 5.7*&

36.5 ± 11.3*&

57.1 ± 4.5*&

0.9 ± 0.2

0.9 ± 0.1

 

Healthy limb

38.2 ± 11.8*

57.2 ± 4.3*

37.5 ± 11.7*

57.2 ± 4.3*

0.9 ± 0.3

0.9 ± 0.2

Normal controls

 

45.6 ± 15.2

60.7 ± 5.2

38.1 ± 11.1

60.5 ± 5.2

0.9 ± 0.2

0.9 ± 0.1

  1. *P < 0.0001, the affected (healthy) limbs of patients with ALS or CSA patients vs. the affected (healthy) limbs of patients with HD.
  2. &P < 0.0001, the affected limbs of patients with HD, ALS or CSA vs. the limbs of normal control.
  3. HD, Hirayama disease; ALS, amyotrophic lateral sclerosis; CSA, cervical spondylotic amyotrophy; CV, conduction velocities; U/M, ulnar/median.